Utilization of Novel Delivery Drug Systems Based on Release of Extracellular Vesicles in Heart Failure
Alexander E Berezin*
Internal Medicine Department, State Medical University, Ukraine
- *Corresponding Author:
- Alexander E Berezin
Professor, MD, PhD, Consultant of Cardiology Unit, Internal Medicine Department
State Medical University, 26, Mayakovsky av., Zaporozhye, Ukraine, Postcode 69035
E-mail: [email protected]
Received date: April 29, 2016; Accepted date: June 06, 2016; Published date: June 15, 2016
Citation: Berezin AE (2016) Utilization of Novel Delivery Drug Systems Based on Release of Extracellular Vesicles in Heart Failure. Cell Dev Biol 5:173. doi:10.4172/2168-9296.1000173
Copyright: © 2016 Berezin AE. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Heart failure (HF) remains to be a serious public and health problem, which associate with higher morbidity, mortality and disability. Although there are high-quality developed clinical recommendations regarding prevention and treatment of HF, patients with HF have experienced the poor clinical outcomes. Currently transfer of drugs using extracellular vesicles (EVs) into target cells in vivo is promising methods for attenuation of cardiac remodeling and ischemia. The mini review is presented data confirming the role of specific novel delivery drug systems released wide spectrum of biological active molecules based on EVs’ releasing in HF. The use of EV systems might allow localized and sustained cytokine release and consequently a prolonged biological effect with induction of tissue regeneration and revascularization in HF.